You are here: Industry Insights > Opdivo

News List

Joining Forces with Zai Lab: What is the Remaining Market Potential for Opdivo in China? Yefenghong
March 06, 2024
Bristol Myers Squibb (BMS) recently announced the transfer of sales rights for one of its core products, the PD-1 monoclonal antibody Opdivo (nivolumab), in select provinces within China to the local biotechnology firm Zai Lab Limited (ZLAB).
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors prnasia
December 13, 2021
Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines...
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carci firstwordpharma
August 26, 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd. (Ono).
US clears BMS' Opdivo as first adjuvant therapy for bladder cancer firstwordpharma
August 23, 2021
Bristol Myers Squibb said Friday that the FDA has expanded Opdivo's (nivolumab) urothelial carcinoma (UC) indication to include adjuvant use in high-risk patients, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.
MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma pharmatimes
August 06, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb's (BMS) Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for the first-line treatment of adult patients with unresectable malignant pleural ...
EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients pharmatimes
August 03, 2021
Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with oesophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease ...
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer pharmatimes
July 01, 2021
The European Commission (EC) has approved Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy immunotherapy regimen for the treatment of certain metastatic colorectal patients (mCRC), the company announced 29th.
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients pharmatimes
June 16, 2021
Bristol Myers Squibb’s (BMS) immunotherapy combination Opdivo plus Yervoy has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of certain advanced bowel cancer patients.
Opdivo combos show OS benefit in advanced oesophageal cancer pharmatimes
June 10, 2021
Bristol Myers Squibb’s (BMS) immunotherapy Opdivo, when administered alongside chemotherapy or Yervoy, demonstrated significant overall survival (OS) benefit compared to chemotherapy alone in advanced/metastatic oesophageal cancer patients.
EC Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma americanpharmaceuticalreview
June 04, 2021
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).